NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/26/2024
Back to search
Official data from USPTO
MOLECULAR CANCER RESEARCH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MOLECULAR CANCER RESEARCH
ST13
US500000076429909Class
16, 41
Filing
76429909
Registration
2783399
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
03/27/2024
Trademark type
Word
Nice classes
16, 41
Filing date
07/03/2002
Registration date
11/11/2003
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/26/2024
Last transaction
03/27/2024
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
11/15/2002
First use in commerce
08/20/2002
Drawing code
1
Owner type
99
Owner location
Philadelphia, PA, US
Examiner
THOMAS, AMY E
Law office
M10
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
American Association for Cancer Research, Inc.
Representatives
Mark A. Steiner, Esq. Duane Morris LLP
Technical classification
Nice Classes
Class 16Class 41
Vienna Codes
No Vienna codes available.
Goods and services
Class 16
Publicationsnamely journals in the field of medicine
Class 41
Providing online publicationsnamely journals in the field of medicine
Publications
History of USPTO decisions and trademark events.
31 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
03/26/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/26/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/26/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
11/01/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
11/11/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/03/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/03/2015
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/16/2014
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
05/16/2014
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/16/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/16/2014
89AF
REGISTERED - COMBINED SECTION 8 (10-YR) & SEC. 9 FILED
05/05/2014
E89R
TEAS SECTION 8 & 9 RECEIVED
05/05/2014
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/03/2012
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/03/2012
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/29/2010
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/25/2010
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
10/30/2009
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/30/2009
ES8R
TEAS SECTION 8 RECEIVED
10/27/2009
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
11/11/2003
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
09/04/2003
IUAA
USE AMENDMENT ACCEPTED
09/04/2003
CFIT
CASE FILE IN TICRS
08/22/2003
IUAF
USE AMENDMENT FILED
07/30/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/30/2003
PAPER RECEIVED
07/30/2003
CNRT
NON-FINAL ACTION MAILED
01/31/2003
DOCK
ASSIGNED TO EXAMINER
01/28/2003
DOCK
ASSIGNED TO EXAMINER
01/09/2003
Continuous trademark protection
Get notified about every new filing that threatens MOLECULAR CANCER RESEARCH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.